Mylotarg (gemtuzumab ozogamicin) is an antibody pharmaceutical. Gemtuzumab ozogamicin was first approved as Mylotarg on 2017-09-01. It is used to treat myeloid leukemia acute and myelomonocytic leukemia acute in the USA. It has been approved in Europe to treat myeloid leukemia acute. The pharmaceutical is active against myeloid cell surface antigen CD33.
|Common Name||Gemtuzumab ozogamicin|
|Indication||myeloid leukemia acute, myelomonocytic leukemia acute|
|Drug Class||Monoclonal antibodies: humanized, tumors as target; antibiotics (Micromonospora strains)|